NeuroOne Medical Technologies Corporation
NMTC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $1 | $3 |
| % Growth | 61.6% | 22.3% | -57.7% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $2 | $1 | $1 | $2 |
| % Margin | 55.8% | 53.9% | 55.6% | 58.9% |
| R&D Expenses | $1 | $1 | $2 | $1 |
| G&A Expenses | $0 | $2 | $0 | $2 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$3 |
| Operating Expenses | $3 | $3 | $3 | $0 |
| Operating Income | -$1 | -$2 | -$3 | $2 |
| % Margin | -50% | -111.2% | -193.3% | 52.3% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | -$2 | -$2 | -$2 | $2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$2 | $2 |
| % Margin | -59.1% | -88.5% | -163.8% | 54.5% |
| EPS | -0.044 | -0.031 | -0.073 | 0.058 |
| % Growth | -42.4% | 57.7% | -226.1% | – |
| EPS Diluted | -0.044 | -0.031 | -0.073 | 0.058 |
| Weighted Avg Shares Out | 40 | 49 | 31 | 31 |
| Weighted Avg Shares Out Dil | 40 | 49 | 31 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$1 | -$2 | $2 |
| % Margin | -56.7% | -84% | -159% | 66.4% |